Corrigendum to “International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer”: [Annals of Oncology 33 (2022) 57-66] (Annals of Oncology (2022) 33(57-66) (S0923753421044963), (10.1016/j.annonc.2021.09.017))
Articolo
Data di Pubblicazione:
2022
Abstract:
The authors regret the affiliation of Dr Paolo Pedrazzoli was incorrectly given in the original article. Dr Pedrazzoli's correct affiliation should read as follows: 24Medical Oncology, Fondazione IRCCS Policlinico S. Matteo and Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy The authors would like to apologise for any inconvenience caused.
Tipologia CRIS:
1.1 Articolo in rivista
Elenco autori:
Novello, S.; Torri, V.; Grohe, C.; Kurz, S.; Serke, M.; Wehler, T.; Meyer, A.; Ladage, D.; Geissler, M.; Colantonio, I.; Cauchi, C.; Stoelben, E.; Ceribelli, A.; Kropf-Sanchen, C.; Valmadre, G.; Borra, G.; Schena, M.; Morabito, A.; Santo, A.; Gregorc, V.; Chiari, R.; Reck, M.; Schmid-Bindert, G.; Folprecht, G.; Griesinger, F.; Follador, A.; Pedrazzoli, P.; Bearz, A.; Caffo, O.; Dickgreber, N. J.; Irtelli, L.; Wiest, G.; Monica, V.; Porcu, L.; Manegold, C.; Scagliotti, G. V.
Link alla scheda completa:
Pubblicato in: